Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
44 hedge funds and large institutions have $25.2M invested in Cidara Therapeutics in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
2.14% less ownership
Funds ownership: 46.61% → 44.48% (-2.1%)
15% less funds holding
Funds holding: 52 → 44 (-8)
36% less capital invested
Capital invested by funds: $39.5M → $25.2M (-$14.2M)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$313K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$178K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$157K |
| 4 |
DMKJ
David M. Knott Jr
|
+$127K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$80.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$332K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$268K |
| 3 |
LCM
Laurion Capital Management
New York
|
-$252K |
| 4 |
Two Sigma Investments
New York
|
-$200K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$185K |
CDTX Hedge Fund Activity: Q1 2022 in Review
44 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q1 2022, worth a combined $25.2M — down 36% from $39.5M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CDTX and 4 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 13 added.
The largest buyer was Monashee Investment Management, opening a new position worth an estimated $313K. The largest seller was Two Sigma Advisers, cutting an estimated $332K.
- 44 institutional investors held Cidara Therapeutics (CDTX) as of Q1 2022, down from 52 in Q4 2021.
- Funds reported $25.2M of Cidara Therapeutics stock for Q1 2022, down 36% quarter-over-quarter.
- 4 funds opened new Cidara Therapeutics positions in Q1 2022 and 12 closed out, a net change of -8 holders.
- The largest Cidara Therapeutics buyer in Q1 2022 was Monashee Investment Management, an estimated $313K added.
- The largest Cidara Therapeutics seller in Q1 2022 was Two Sigma Advisers, an estimated $332K sold.
Based on aggregated 13F filings for Q1 2022.